Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump administration buffets global trade with tariffs.
Categories:
Related Post
Trades skills course provides second chances
GAF Roofing Academy’s free weeklong training seeks to get students, some of whom have been…
Office conversions accelerate, but many older buildings face demolition: reports
High vacancy rates have driven building owners to repurpose space, which should help the U.S.…
Construction’s labor demand gap forecast shrinks
Down from half a million in recent years, contractors will still need hundreds of thousands…